KCTD1 stabilizes c-Myc to upregulate PD-L1 and suppress anti-tumor immunity in hepatocellular carcinoma - PubMed
4 hours ago
- #PD-L1
- #Immune Evasion
- #Hepatocellular Carcinoma
- KCTD1 stabilizes c-Myc to upregulate PD-L1, suppressing anti-tumor immunity in hepatocellular carcinoma (HCC).
- HCC accounts for 90% of primary liver cancer cases globally, with immune checkpoint blockade (ICB) therapies showing varied responses.
- KCTD1 enhances PD-L1 expression by interacting with c-Myc via its BTB domain and c-Myc's BR-HLH-LZ domain.
- Knockdown of KCTD1 reduces c-Myc and PD-L1 levels, increases pro-inflammatory cytokines (IFN-γ, TNF-α), and boosts CD8+ T cell activity.
- In murine models, KCTD1 knockdown combined with anti-PD-1 therapy improves tumor infiltration by T cells and enhances anti-tumor efficacy.
- KCTD1 is identified as a key regulator of immune evasion in HCC, offering a potential target to improve immune checkpoint therapy.